Post-ERCP Pancreatitis Clinical Trial
Official title:
Timing of Oral Refeeding in Post-ERCP Pancreatitis
Endoscopic retrograde cholangio-pancreatography (ERCP) is the most commonly used technique for diagnosis and treatment in the treatment of bile duct diseases including bile duct cholelithiasis and malignant/benign biliary obstruction. In particular, ERCP is an essential procedure for the removal of bile duct gallstones and bile drainage in malignant/benign biliary obstruction patients. Among ERCP-related complications, especially "post-ERCP pancreatitis (PEP)", which occurs due to the anatomical structure of the pancreatic biliary system, statistically occurs in about 5-10% of patients who first received ERCP. It is known, and treatment for PEP is the same as treatment for general acute pancreatitis but is known to have a relatively worse prognosis. The basis of treatment for acute pancreatitis is a conservative treatment based on fasting and fluid treatment, and starting oral diet after abdominal pain and pancreatic enzyme levels (amylase/lipase) normalized. However, a recent study reported that early oral diet could improve the patient's prognosis. According to a systematic review of 11 randomized trial papers by Valerie et al., it was reported that the early diet had the effect of reducing hospital stay without increasing adverse events when comparing the prognosis of the early refeeding group and delayed refeeding group. This result is theoretically considered to be because the oral diet has the advantage of increasing intestinal permeability, gut motility and reducing the likelihood of pancreatic necrosis/ infection compared to the parenteral diet. As above, PEP has the same treatment method as general acute pancreatitis but is known to have a relatively worse prognosis. However, the effect of an early diet recently attempted in acute pancreatitis has not been reported in patients with PEP. Therefore, we investigate the effects of early and delayed diets on the prognosis of patients with PEP through a prospective multicenter study.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | December 30, 2022 |
Est. primary completion date | November 10, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Patients aged 20 to 80 2. As patients who developed pancreatitis after receiving ERCP, the following must be satisfied at the same time. 1. increased serum amylase or lipase 3 times higher than the normal range, at 4 hours after ERCP or the morning of the following day, 2. New or worsening abdominal pain compatible with pancreatitis, arising 4 hours after ERCP or the next morning Exclusion Criteria: 1. If the intended procedure is not completed 2. If complications such as abdominal perforation or bleeding have occurred or are suspected 3. If it is judged as severe acute pancreatitis with multi-organ failure la. 4. When PEP has occurred, but additional imaging tests and endoscopy for diagnosis of the underlying disease or treatment of complications of the patient are required, and fasting is necessary regardless of this study 5. Patients with a history of chronic pancreatitis 6. Pregnant women, lactating women |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Korea University Ansan Hospital | Ansan-si | |
Korea, Republic of | Pusan National University Hospital | Busan | |
Korea, Republic of | Gyeongsang National University Changwon Hospital | Changwon | |
Korea, Republic of | Kyungpook National University School of Medicine | Daegu | |
Korea, Republic of | Gachon University College of Medicine | Incheon | |
Korea, Republic of | Seoul Metropolitan Government Boramae Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Seoul St. Mary's Hospital | Seoul | |
Korea, Republic of | Yonsei University College of Medicine | Seoul |
Lead Sponsor | Collaborator |
---|---|
Yonsei University |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | hospitalization period for PEP | If the patient is tolerable for more than 24 hours after the soft diet (abdominal pain improvement, lab amylase/lipase level decreases to less than 2 times the upper normal limit, it is judged that PEP has improved and the discharge criteria have been satisfied. From the point of diagnosis of PEP to the point of time when the discharge criteria are satisfied is defined as the "hospitalization period for PEP". | up to 1 month | |
Secondary | Incidence of acute severe pancreatitis | comparing rate of incidence of severe acute pancreatitis | up to 1 month | |
Secondary | readmission rate (<30 days) | comparing readmission rate of each group until 30 days after discharge | up to 1 month | |
Secondary | mortality rate | comparing mortality rat of each group during hospitalization | up to 1 month | |
Secondary | complication rate | comparing complication rate including nausea/vomiting, recurrent abdominal pain, necrotizing pancreatitis of each group during hospitalization | up to 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02476279 -
Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis
|
Phase 3 | |
Unknown status |
NCT01771419 -
Comparison Of Loop-Tip Wire Vs Tradictional Technique In The Cannulation Of The Common Bile Duct
|
N/A | |
Completed |
NCT04876768 -
Effects of High FIO2 on Post-ERCP Pancreatitis.
|
N/A | |
Not yet recruiting |
NCT06250803 -
Early Pancreatic Stent Placement for Preventing PEP
|
N/A | |
Completed |
NCT01912716 -
Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis
|
Phase 2/Phase 3 | |
Terminated |
NCT00820612 -
Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients
|
Phase 4 | |
Completed |
NCT03643900 -
The Efficacy of Pancreatic Duct Stenting With Rectal Indomethacin in Preventing Post-ERCP Pancreatitis
|
N/A | |
Terminated |
NCT03749590 -
Magnesium Sulfate in the Prevention of Post-ERCP Pancreatitis.
|
Phase 3 | |
Recruiting |
NCT03708458 -
Pharmacological Prophylaxis of Post- Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
|
Phase 4 |